Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX stock opened at $1.01 on Friday. The firm’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.82. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm has a market cap of $59.41 million, a P/E ratio of -0.44 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Featured Articles

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.